Distinguished in Ulcerative Colitis

Dr. Joel R. Rosh

Pediatric Gastroenterology | Pediatrics
100 Madison Avenue, 
Morristown, NJ 
Clinical Trials:Currently Recruiting for 1 Trial
Distinguished in Ulcerative Colitis
100 Madison Avenue, 
Morristown, NJ 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Joel Rosh is a Pediatric Gastroenterologist and a Pediatrics provider in Morristown, New Jersey. Dr. Rosh is rated as a Distinguished provider by MediFind in the treatment of Ulcerative Colitis. His top areas of expertise are Viral Gastroenteritis, Crohn's Disease, Colitis, Endoscopy, and Colonoscopy.

His clinical research consists of co-authoring 103 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 37 articles and participated in 3 clinical trials in the study of Ulcerative Colitis.

Specialties
Pediatric Gastroenterology
Pediatrics
Licenses
Pediatric Gastroenterology in NJ
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health First
  • HMO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Northwell Health
  • INSURANCE PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 3 Less Insurance Carriers -

Locations

100 Madison Avenue, Morristown, NJ 07960

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Randomized, Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of Vedolizumab Intravenous as Maintenance Therapy in Pediatric Subjects With Moderately to Severely Active Crohn's Disease Who Achieved Clinical Response Following Open-Label Vedolizumab Intravenous Therapy
A Randomized, Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of Vedolizumab Intravenous as Maintenance Therapy in Pediatric Subjects With Moderately to Severely Active Crohn's Disease Who Achieved Clinical Response Following Open-Label Vedolizumab Intravenous Therapy
Enrollment Status: Recruiting
Publish Date: January 20, 2025
Intervention Type: Drug
Study Drug: Vedolizumab
Study Phase: Phase 3
A Randomized, Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of Vedolizumab Intravenous as Maintenance Therapy in Pediatric Subjects With Moderately to Severely Active Ulcerative Colitis Who Achieved Clinical Response Following Open-Label Vedolizumab Intravenous Therapy
A Randomized, Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of Vedolizumab Intravenous as Maintenance Therapy in Pediatric Subjects With Moderately to Severely Active Ulcerative Colitis Who Achieved Clinical Response Following Open-Label Vedolizumab Intravenous Therapy
Enrollment Status: Completed
Publish Date: October 01, 2025
Intervention Type: Drug
Study Drug: Vedolizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease
Enrollment Status: Completed
Publish Date: December 27, 2024
Intervention Type: Drug
Study Drugs: Mirikizumab, Ustekinumab
Study Phase: Phase 3
A Multicenter, Open-Label PK Study of Mirikizumab in Pediatric Patients With Moderately to Severely Active Ulcerative Colitis
A Multicenter, Open-Label PK Study of Mirikizumab in Pediatric Patients With Moderately to Severely Active Ulcerative Colitis
Enrollment Status: Completed
Publish Date: March 26, 2024
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 2
Predicting Response to Vedolizumab in Pediatric Inflammatory Bowel Diseases (IBD) Including Drug Levels: a Multi-center Prospective Cohort Study, From the Pediatric IBD Porto Group of European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN)
Predicting Response to Vedolizumab in Pediatric Inflammatory Bowel Diseases (IBD) Including Drug Levels: a Multi-center Prospective Cohort Study, From the Pediatric IBD Porto Group of European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN)
Enrollment Status: Completed
Publish Date: October 25, 2022
Intervention Type: Drug
Study Drug: Vedolizumab
Study Phase: Not Applicable
View 4 Less Clinical Trials

103 Total Publications

Children With Inflammatory Bowel Diseases are Disadvantaged by Current Drug Approval Policies: A Call for Urgent Change.
Children With Inflammatory Bowel Diseases are Disadvantaged by Current Drug Approval Policies: A Call for Urgent Change.
Journal: Crohn's & colitis 360
Published: March 27, 2025
Similar Doctors
Elite in Ulcerative Colitis
Dr. Neal S. Leleiko
Pediatric Gastroenterology | Pediatrics
Elite in Ulcerative Colitis
Dr. Neal S. Leleiko
Pediatric Gastroenterology | Pediatrics
3959 Broadway Fl 7, 
New York, NY 
 (27.5 miles away)
212-305-5903
Languages Spoken:
English
See accepted insurances

Neal Leleiko is a Pediatric Gastroenterologist and a Pediatrics provider in New York, New York. Dr. Leleiko is rated as a Distinguished provider by MediFind in the treatment of Ulcerative Colitis. His top areas of expertise are Viral Gastroenteritis, Ulcerative Colitis, Hemorrhagic Proctocolitis, Colonoscopy, and Endoscopy.

Distinguished in Ulcerative Colitis
Dr. Michael T. Dolinger
Pediatric Gastroenterology | Pediatrics
Distinguished in Ulcerative Colitis
Dr. Michael T. Dolinger
Pediatric Gastroenterology | Pediatrics

New York University

111 Broadway, 
New York, NY 
 (24.4 miles away)
212-263-9700
Languages Spoken:
English
See accepted insurances

Michael Dolinger is a Pediatric Gastroenterologist and a Pediatrics provider in New York, New York. Dr. Dolinger is rated as a Distinguished provider by MediFind in the treatment of Ulcerative Colitis. His top areas of expertise are Crohn's Disease, Ulcerative Colitis, Hemorrhagic Proctocolitis, Endoscopy, and Colonoscopy.

Distinguished in Ulcerative Colitis
Dr. James F. Markowitz
Pediatric Gastroenterology | Pediatrics
Distinguished in Ulcerative Colitis
Dr. James F. Markowitz
Pediatric Gastroenterology | Pediatrics
Sch - Pediatric Gastroenterology, 269-01 76th Avenue, 
New Hyde Park, NY 
 (41.2 miles away)
516-470-3430
Languages Spoken:
English
See accepted insurances

James Markowitz is a Pediatric Gastroenterologist and a Pediatrics provider in New Hyde Park, New York. Dr. Markowitz is rated as a Distinguished provider by MediFind in the treatment of Ulcerative Colitis. His top areas of expertise are Viral Gastroenteritis, Crohn's Disease, Ulcerative Colitis, Colonoscopy, and Endoscopy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Rosh's expertise for a condition
ConditionClose
    View All 11 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile